Reconfigurable Intelligent Surfaces Aided mmWave NOMA: Joint Power Allocation,Phase Shifts, and Hybrid Beamforming Optimization

In this paper, an reconfigurable intelligent surface (RIS)-aided millimeter wave (mmWave) non-orthogonal multiple access (NOMA) system is considered. In particular, we consider an RIS-aided mmWave-NOMA downlink system with a hybrid beamforming structure. To maximize the achievable sum-rate under a minimum rate constraint for the users and a minimum transmit power constraint, a joint RIS phase shifts, hybrid beamforming, and power allocation problem is formulated. To solve this non-convex optimization problem, we develop an alternating optimization algorithm. Specifically, first, the non-convex problem is transformed into three subproblems, i.e., power allocation, joint phase shifts and analog beamforming optimization, and digital beamforming design. Then, we solve the power allocation problem under fixed phase shifts of the RIS and hybrid beamforming. Finally, given the power allocation matrix, an alternating manifold optimization (AMO)-based method and a successive convex approximation (SCA)-based method are utilized to design the phase shifts, analog beamforming, and transmit beamforming, respectively. Numerical results reveal that the proposed alternating optimization algorithm outperforms state-of-the-art schemes in terms of sum-rate. Moreover, compared to a conventional mmWave-NOMA system without RIS, the proposed RIS-aided mmWave-NOMA system is capable of improving the achievable sum-rate of the system

MMP-9, a Potential Target for Cerebral Ischemic Treatment

Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases

Anti-hyperuricemic effect of Plantago depressa Willd extract in rats

Purpose: To investigate the effects of Plantago depressa Willd. extract (PDWE) on hyperuricemia in rats.Methods: The effect of PDWE was investigated in hyperuricemic rats induced by potassium oxonate. PDWE were fed to hyperuricemic rats daily at a dose of 160, 320 and 640 mg/kg for 10 days; allopurinol (5 mg/kg) was given as positive control. Serum and urine levels of uric acid and creatinine were determined by colorimetric method.Results: PDWE inhibited xanthine oxidase (XOD) activity in serum (16.36 ± 1.16 U/L, p < 0.05) and liver (72.15 ± 5.26 U/g protein, p < 0.05), and also decreased levels of serum uric acid (2.43 ± 0.59 mg/L, p < 0.05), serum creatinine (0.42 ± 0.15 μmol/L) and blood urea nitrogen (BUN, 9.58 ± 0.72 mmol/L, p < 0.05), but increased levels of urine uric acid (39.23 ± 8.22 mg/L, p < 0.05) and urine creatinine (32.24 ± 1.69 mmol/L, p < 0.05) in the renal tissue of hyperuricemic rats.Conclusion: PDWE exerts uricosuric action by regulating renal urate transporters to ameliorate renal dysfunction in hyperuricemic rats.Keywords: Plantago depressa Willd., Hyperuricemic, Renal urate transporters, Renal dysfunction, Uricosuric actio

Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome

Studies have shown that the natural flavonoid luteolin has neurotrophic activity. In this study, we investigated the effect of luteolin in a mouse model of Down syndrome. Ts65Dn mice, which are frequently used as a model of Down syndrome, were intraperitoneally injected with 10 mg/kg luteolin for 4 consecutive weeks starting at 12 weeks of age. The Morris water maze test was used to evaluate learning and memory abilities, and the novel object recognition test was used to assess recognition memory. Immunohistochemistry was performed for the neural stem cell marker nestin, the astrocyte marker glial fibrillary acidic protein, the immature neuron marker DCX, the mature neuron marker NeuN, and the cell proliferation marker Ki67 in the hippocampal dentate gyrus. Nissl staining was used to observe changes in morphology and to quantify cells in the dentate gyrus. Western blot assay was used to analyze the protein levels of brain-derived neurotrophic factor (BDNF) and phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2) in the hippocampus. Luteolin improved learning and memory abilities as well as novel object recognition ability, and enhanced the proliferation of neurons in the hippocampal dentate gyrus. Furthermore, luteolin increased expression of nestin and glial fibrillary acidic protein, increased the number of DCX+ neurons in the granular layer and NeuN+ neurons in the subgranular region of the dentate gyrus, and increased the protein levels of BDNF and p-ERK1/2 in the hippocampus. Our findings show that luteolin improves behavioral performance and promotes hippocampal neurogenesis in Ts65Dn mice. Moreover, these effects might be associated with the activation of the BDNF/ERK1/2 pathway

Association of hematological parameters with metabolic syndrome in Beijing adult population: a longitudinal study

The purposes of the study were to estimate the incidence of metabolic syndrome (MetS) and to systematically evaluate the relationship between hematological parameters and MetS in a 5-year follow-up of Beijing adult population. The longitudinal study included 3,180 adults, aged 20–65 years, who attended health check-ups in Beijing Tongren Hospital in 2007 and 2012. Multivariate logistic regression was conducted to explore the associations between hematological parameters and MetS. The 5-year cumulative incidence of MetS in this sample was 10.82 % (14.22 % for males and 7.59 % for females). Among all the hematological parameters, white blood cell count (WBC) was positively associated with MetS for 20–35-year-old (male OR 1.482, 95 % CI 1.169–2.974; female OR 1.398, 95 % CI 1.145–3.011), and 36–50-year-old (male OR 2.012, 95 % CI 1.290–4.010; female OR 3.400, 95 % CI 1.818–4.528) male and female subjects. Alanine aminotransferase (ALT) was significantly associated with the incidence of MetS for males (20–35-year-old OR 2.080, 95 % CI 1.371–3.159; 36–50-year-old OR 2.421, 95 % CI 1.335–3.412; 51–65-year-old OR 4.267, 95 % CI 1.161–6.781). Low-density lipoprotein cholesterol (LDL-C) was positively associated with MetS for 51–65-year-old (male OR 3.078, 95 % CI 2.468–5.131; female OR 2.140, 95 %CI 1.524–4.359) for male and female subjects. WBC is positively associated with MetS for young adults, while LDL-C is positively associated with MetS for elderly people. ALT is positively associated with MetS for males. Our findings provide further evidence in support of using hematological markers for early detection of individuals at risk for MetS

A mouse line for inducible and reversible silencing of specific neurons

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Acknowledgements: We thank Dr. Joseph W. Lynch for sharing the IVMR plasmid, and Dr. Lisa M. Monteggia for sharing the AAV2-Cre plasmid. Rosa-CAG targeting vector was obtained from Addgenes. This work was supported by the Key State Research Program from Ministry of Science and Technology of China (2011CB510005, 2012CB966900, 2013CB835103), National Natural Science Foundation of China (81221001, 81200692, 81101026, 31100788, 31271182, 31030034, 91232724), Science and Technology Commission of Shanghai Municipality (12XD1404800), Shanghai Pujiang Program (12PJ1408800), Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2014-04) and Sino-UK Higher Education Research Partnership for PhD Studies.Peer reviewedPublisher PD

Association of choroidal thickness with early stages of diabetic retinopathy in type 2 diabetes

AIM: To assess the correlation between choroidal thickness (CT) and the early stages of diabetic retinopathy (DR) in type 2 diabetic patients. METHODS: We divided 83 diabetic patients (51-80 years of age; 50 females) into non diabetic retinopathy group (NDR) and mild/moderate nonproliferative diabetic retinopathy (NPDR) group, and compared them with 26 non-diabetic control subjects (51-78 years of age; 16 females). Subfoveal choroidal thickness (SFCT) and parafoveal choroidal thickness (PFCT) were measured using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Ocular health status, disease duration, body mass index, and hemoglobin A1c (HbA1c) were recorded. RESULTS: The mean ages of the NDR, NPDR, and control groups were 68.0±6.9y, 67.8±6.4y, and 65.1±6.3y, respectively (P=0.17). Pearson correlation of the right and left eyes for the control subjects was 0.95 and for the NDR subjects was 0.93. SFCT for the right eyes of the controls was 252.77± 41.10 μm, which was significantly thicker than that of the right eyes in NDR group (221.51±46.56 μm) and the worse eyes of the NPDR group (207.18±61.87 μm; ANOVA, P<0.01). In the diabetic patients pooled together, age was the only variable significantly associated with SFCT (multiple linear regression analysis, P=0.01). CONCLUSION: CT decreased significantly in the NDR and mild/moderate NPDR eyes compared with the control eyes. Age is significantly associated with SFCT in the diabetic patients. Diabetic choroidopathy may be present before clinical retinopathy